Clinical trials: Chikungunya Fever
Chikungunya Virus Infection
Chikungunya Virus Detection in Semen
Chikungunya is an arboviral disease transmitted by Aedes mosquitoes, present in intertropical zones and Europe. In August 2024, autochthonous cases appeared on Réunion, followed by a large epidemic.
- Trial name
- CHIKSPERM (NCT06983548)
- Testing
- semen, blood and urine tests
- Where
- 2 sites in France
- Volunteers
- 15 people
- Sponsor
- University Hospital, Toulouse
Chikungunya Virus Infection, Neonatal
Against Chikungunya Virus and Neonatal Infection
The goal of this clinical trial is to learn if administration of plasma, from a whole blood donation from an individual who has declared a Chikungunya infection for less than 6 months , to a newborn, whose mother has a peripartum…
- Conditions
- Chikungunya Virus Infection, Neonatal, Transfusion, Encephalopathy
- Trial name
- ConvictionCHIK (NCT07190560)
- Testing
- plasma transfusion : PC-CHIK-V
- Where
- 3 sites in France, French Guiana and 1 more
- Volunteers
- 60 people
- Sponsor
- Centre Hospitalier Universitaire de la Réunion
Chikungunya Virus Infection
A Phase 2 Clinical Trial of VLA1553 in Healthy Children Aged 1 to 11 Years
This is a multicenter, prospective, randomized, observer-blinded, three arm, phase 2 clinical trial evaluating the full dose formulation of VLA1553, half dose formulation of VLA1553 and control.
- Trial name
- NCT06106581
- Testing
- VLA1553 full dose, VLA1553 half dose, Control
- Where
- 3 sites in Dominican Republic, Honduras
- Volunteers
- 304 people, healthy volunteers welcome
- Sponsor
- Valneva Austria GmbH
Chikungunya
Study to Assess the Safety and Immunogenicity of a Chikungunya Virus Vaccine Candidate (VLA1553) in Healthy Volunteers
Randomized, observer-blinded, multicenter, dose-escalation Phase 1 clinical study investigating three dose levels of VLA1553 after a single immunization.
- Trial name
- NCT03382964
- Testing
- VLA1553
- Where
- 2 sites in United States
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Valneva Austria GmbH
Chikungunya
Study of a Live Attenuated Chikungunya Vaccine in a Previously Epidemic Area
The clinical study primarily assesses the safety of MV-CHIK a new Chikungunya vaccine in a previously epidemic area in healthy volunteers. Secondarily, immune response and viremia will be assessed.
- Trial name
- NCT03101111
- Testing
- MV-CHIK, MMR-vaccine
- Where
- Puerto Rico
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Themis Bioscience GmbH
Viral Vaccines, Chikungunya Fever
Chikungunya Virus Vaccine Trial in Healthy Adults
Background: Chikungunya virus (CHIKV) is transmitted by mosquitoes. It can cause fever, headache, muscle pain, fatigue, and joint pain. The disease usually does not cause death.
- Conditions
- Viral Vaccines, Chikungunya Fever, Chikungunya Virus Infection
- Trial name
- NCT01489358
- Testing
- VRC-CHKVLP059-00-VP
- Where
- United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Chikungunya Virus Infection
Clinical Evaluation of Anti-CHIKV Hyperimmune Intravenous Immunoglobulins
Chikungunya virus (CHIKV) has been detected in humans in the Caribbean area for the first time in November 2013 (St-Martin Island).
- Trial name
- CHIKIVIG-01 (NCT02230163)
- Testing
- anti-CHIKV hyperimmune immunoglobulins
- Where
- 3 sites in France
- Volunteers
- 40 people
- Sponsor
- Centre Hospitalier Universitaire de la Guadeloupe
Arbovirus Infections
The Interest of Systematic Screening for Dengue, Chikungunya, and Zika, in Malaria-negative Return Travelers
International travel has increased dramatically in recent years. Vector-borne pathologies such as malaria and arboviruses are common etiologies of post-travel fever, which are prevalent in similar geographical areas (tropical and…
- Trial name
- NCT06651372
- Testing
- The retrospective analyses planned for these samples consist of serological analysis and molecular analysis (RT-PCR ) according to the date of symptoms ons
- Where
- France
- Volunteers
- 200 people
- Sponsor
- University Hospital, Strasbourg, France
Chikungunya
A Multicenter Study to Evaluate Safety and Immunogenicity of a Live-attenuated Chikungunya Vaccine in Adolescents
This was a prospective, randomized, double-blinded, multicenter, pivotal study evaluating the full dose of VLA1553 (1 x10E4 TCID50 per dose) in comparison to a placebo control.
- Trial name
- NCT04650399
- Testing
- Active
- Where
- 10 sites in Brazil
- Volunteers
- 754 people, healthy volunteers welcome
- Sponsor
- Butantan Institute
Zika Virus, Dengue Virus
Zika Virus and Related Arbovirus Infections in Deferred Blood Donors (ZVADD)
Background: Zika virus is mostly passed on by the bite of an infected mosquito. It usually causes mild illness. But in pregnant women it can cause serious birth defects to the baby.
- Conditions
- Zika Virus, Dengue Virus, Chikungunya Virus Infections
- Trial name
- NCT02794181
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Zika Virus, Pregnancy Related
ZIKAlliance Pregnant Women Cohort
The aim of this proposal is to evaluate the causal relationship between Zika virus (ZIKV) infections in pregnancy and congenital malformations.
- Trial name
- ZIKAlliancePW (NCT03188731)
- Where
- 14 sites in Bolivia, Brazil and 5 more
- Volunteers
- 3,852 people, healthy volunteers welcome
- Sponsor
- University of Heidelberg Medical Center
HIV Infections, Chikungunya Virus Infection
Seroprevalence of Chikungunya at the End of the First Chikungunya Outbreak in the French Antilles Within a Sample of Patients Treated for a HIV Infection
Late 2013, the first indigenous cases of chikungunya have been observed in the French Antilles. At the end of May 2014, almost all of the islands of the Caribbean were affected by the outbreak.
- Trial name
- ChikVIH (NCT02553369)
- Testing
- Biological sample collection
- Where
- 2 sites in France
- Volunteers
- 388 people
- Sponsor
- University Hospital Center of Martinique
Chikungunya Virus Infection
Real-world Effectiveness, Safety & Immunogenicity of Chikungunya Vaccination: Ambispective Study in Reunion & French Guiana
In the context of the ongoing chikungunya epidemic in Réunion Island and the anticipated epidemic in French Guiana, the investigators propose an ambispective study to evaluate the real-world effectiveness, safety, and…
- Trial name
- CHIK-RE-VAC (NCT06928753)
- Testing
- IXCHIQ, VIMKUNYA
- Where
- 2 sites in French Guiana, Reunion
- Volunteers
- 1,505 people
- Sponsor
- Centre Hospitalier Universitaire de la Réunion
Chikungunya Fever
Safety and Immunogenicity of a Candidate CHIKV Vaccine (CHIK001)
A phase I dose escalation study to assess the safety and immunogenicity of the candidate vaccine ChAdOx1 Chik in healthy volunteers. Volunteers will be recruited and vaccinated in Oxford, England.
- Trial name
- NCT03590392
- Testing
- ChAdOx1 Chik
- Where
- United Kingdom
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Chikungunya
Post-Chikungunya Rheumatism - Rheumatology Follow-up of Patients After 15 Years
Reunion Island was struck by a severe Chikungunya outbreak in 2005-2006. Three hundred and seven Chikungunya patients were evaluated by 4 rheumatologists 2 months after the initial infection (RHUMATOCHIK study).
- Trial name
- ChikRhuma15 (NCT04838574)
- Testing
- 15 years Follow-up group
- Where
- 3 sites in Reunion
- Volunteers
- 152 people
- Sponsor
- Centre Hospitalier Universitaire de la Réunion
Infected by Chikungunya Virus
Study of the Prognostic Value of Musculoskeletal Ultrasound in Adults With Chikungunya
Chikungunya is a viral disease transmitted by mosquitoes whose clinical feature is the early joint damage. Approximately 8% of patients have chronic arthropathy resembling to the rheumatoid polyarthritis.
- Trial name
- EchoCHIK (NCT02281123)
- Testing
- SF36 (QQoL)
- Where
- Martinique
- Volunteers
- 200 people
- Sponsor
- University Hospital Center of Martinique
Dengue, Zika
Testing Combined IIT-SIT to Control Mosquito-Borne Diseases At Scale
Mosquito-borne diseases cause suffering for hundreds of millions of people and claim more than 700,000 lives yearly. Diseases such as dengue, Zika, and chikungunya cause symptoms similar to malaria and are endemic in many parts…
- Conditions
- Dengue, Zika, Chikungunya
- Trial name
- NCT06595745
- Testing
- Wolbachia induced incompatible mating, Standard traditional chemical mosquito control
- Where
- Mexico
- Volunteers
- 15,243 people, healthy volunteers welcome
- Sponsor
- Michigan State University
Chikungunya Virus Infection
Phase I Trial of Measles Vectored Chikungungya Vaccine
This study is a randomized, double-blinded, Phase 1, placebo- controlled, and dose comparison trial to evaluate the safety, immunogenicity and schedule of MV-CHIK. Two dosage levels and 3 immunization schedules will be evaluated.
- Trial name
- NCT03028441
- Testing
- VRC-CHKVLP059-00-VP
- Where
- 3 sites in United States
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Encephalitis, Myelitis
Neurologic Manifestations of the Arbovirus Infection in Colombia
This is a multi-center case-control study that aims to define the association between the exposure to an arbovirus infection and the development of a neurological syndrome in patients from Colombia.
- Conditions
- Encephalitis, Myelitis, Guillain-Barre Syndrome, Cranial Nerve Palsies
- Trial name
- NCT03206541
- Where
- 8 sites in Colombia
- Volunteers
- 570 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University
Arbovirus Infections
Spatial Repellents for Arbovirus Control
Dengue viruses are the most medically important arthropod-borne pathogens worldwide, with transmission occurring in most tropical and sub-tropical regions. An estimated 390 million infections occur yearly.
- Trial name
- NCT03553277
- Testing
- transfluthrin
- Where
- Peru
- Volunteers
- 18,240 people, healthy volunteers welcome
- Sponsor
- University of Notre Dame